Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced

See also
Status	Clinical Trial	Phase
Completed	`NCT00547846` - A Phase II Clinical Study of PDC-748 in Patients With Acute Cough	Phase 2
Completed	`NCT01597349` - Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection	Phase 2
Completed	`NCT02396706` - RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT00547846 - A Phase II Clinical Study of PDC-748 in Patients With Acute Cough

Phase 2

Completed

NCT01597349 - Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

Phase 2

Completed

NCT02396706 - RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03569033
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Terminated
Phase	Phase 2
Start date	July 4, 2018
Completion date	November 19, 2018

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms